Ardelyx (ARDX)
(Delayed Data from NSDQ)
$6.21 USD
+0.26 (4.37%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $6.21 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Brokerage Reports
0 items in cart
Ardelyx, Inc. [ARDX]
Reports for Purchase
Showing records 161 - 175 ( 175 total )
Company: Ardelyx, Inc.
Industry: Medical - Drugs
4Q14 Earnings, Oversold Shares Provides Attractive Entry Point, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Ardelyx, Inc.
Industry: Medical - Drugs
Releases Additional Data from Phase IIb ESRD Trial, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Ardelyx, Inc.
Industry: Medical - Drugs
Releases Additional Data from Phase IIb ESRD Trial, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Ardelyx, Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of Jan 12
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Ardelyx, Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of Jan 5
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Ardelyx, Inc.
Industry: Medical - Drugs
Q3:14 Earnings, Accelerated Data Release for Tenapanor Phase 2b Study in ESRD
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Ardelyx, Inc.
Industry: Medical - Drugs
Tenapanor Meets Primary Endpoint in IBS-C, Data Compare Favorably with Linzess, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Ardelyx, Inc.
Industry: Medical - Drugs
Tenapanor Meets Primary Endpoint in IBS-C, Data Compare Favorably with Linzess, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Ardelyx, Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of Sept 29
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Ardelyx, Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of Sept 22
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Ardelyx, Inc.
Industry: Medical - Drugs
Company: Ardelyx, Inc.
Industry: Medical - Drugs
Company: Ardelyx, Inc.
Industry: Medical - Drugs
Q2:14 Earnings, Multiple Near-Term Catalysts Ahead, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Ardelyx, Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of July 21
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Ardelyx, Inc.
Industry: Medical - Drugs
Initiating coverage with an OUTPERFORM and $31 price target
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D